{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-029717","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2025-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.134292+00:00","generated_at":"2026-05-17T05:51:23.329416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k","bullets":["Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.","Q4 net loss $178k ($0.01 loss per share) vs net income $268k ($0.01 EPS) prior year; tax expense $773k.","FY2025 revenue $54.4M (+8.0%); net income $808k ($0.03 diluted EPS) vs $112k ($0.00 EPS) prior year.","FY operating income $2.0M vs $251k; selling and administrative expenses flat.","Weighted average diluted shares for FY 31.2M vs 30.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-029717","json":"https://secwatch.observer/filing/0001437749-25-029717.json","markdown":"https://secwatch.observer/filing/0001437749-25-029717.md","text":"https://secwatch.observer/filing/0001437749-25-029717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774925029717/0001437749-25-029717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774925029717/inbp20250922_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:51:23.329416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}